BACKGROUND AND AIM: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. MATERIALS AND METHODS: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. RESULTS: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128). CONCLUSIONS: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.
BACKGROUND AND AIM: Translational data suggest that nucleoside transporters, in particular humanequilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. MATERIALS AND METHODS: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. RESULTS: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128). CONCLUSIONS: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.
Authors: Ting Deng; Hong Pan; Rubing Han; Dingzhi Huang; Hongli Li; Likun Zhou; Xia Wang; Ming Bai; Xiang Li; Rui Liu; Shaohua Ge; Tao Ning; Le Zhang; Yi Ba Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Christina H Wei; Tristan R Gorgan; David A Elashoff; O Joe Hines; James J Farrell; Timothy R Donahue Journal: Pancreas Date: 2013-11 Impact factor: 3.327
Authors: Bruno Vincenzi; Silvia Stacchiotti; Paola Collini; Francesco Pantano; Carla Rabitti; Giuseppe Perrone; Michele Iuliani; Alfonso Baldi; Giuseppe Badalamenti; Roberta Sanfilippo; Daniele Santini; Andrea Onetti Muda; Alessandro Gronchi; Paolo Casali; Angelo Paolo Dei Tos; Giuseppe Tonini Journal: Br J Cancer Date: 2017-06-22 Impact factor: 7.640
Authors: Giovanni Brandi; Marzia Deserti; Francesco Vasuri; Andrea Farioli; Alessio Degiovanni; Andrea Palloni; Giorgio Frega; Maria A Barbera; Stefania de Lorenzo; Ingrid Garajova; Mariacristina Di Marco; Antonio D Pinna; Matteo Cescon; Alessandro Cucchetti; Giorgio Ercolani; Antonietta D'Errico-Grigioni; Maria A Pantaleo; Guido Biasco; Simona Tavolari Journal: Oncologist Date: 2016-03-31
Authors: Siennah R Miller; Xiaohong Zhang; Raymond K Hau; Joseph L Jilek; Erin Q Jennings; James J Galligan; Daniel H Foil; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington Journal: Mol Pharmacol Date: 2020-12-01 Impact factor: 4.436